Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.58
$0.063.95%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.24% | 207.45% | 274.73% | -111.39% | -46.76% |
| Total Depreciation and Amortization | 7.45% | 6.71% | 7.87% | 8.87% | 15.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.41% | -59.14% | 231.44% | 113.38% | -20.63% |
| Change in Net Operating Assets | -122.76% | -144.34% | 72.42% | 81.36% | 1,251.57% |
| Cash from Operations | -220.77% | 11.02% | 159.60% | -172.59% | 239.69% |
| Capital Expenditure | 48.83% | -70.00% | 80.54% | 15.69% | -141.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.00% | -16,090.22% | 199.90% | 55.56% | -100.16% |
| Cash from Investing | 48.51% | -4,379.53% | 197.36% | 18.92% | -112.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -14.29% | 300.00% | 77.78% | 44.44% | 83.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.45% | -337.10% | 114.44% | -125.15% | -77.55% |